Melinta Therapeutics to Present at 34th Annual J.P. Morgan Healthcare Conference
January 05, 2016 08:00 ET
|
Melinta Therapeutics
New Haven, CT, Jan. 05, 2016 (GLOBE NEWSWIRE) -- Melinta Therapeutics today announced that Dr. Eugene Sun, the Company’s interim Chief Executive Officer, will be providing a corporate update at...
Melinta Therapeutics Presents Complete Delafloxacin Results from Phase 3 Study in Patients with Acute Bacterial Skin and Skin Structure Infections at ID Week
October 09, 2015 15:30 ET
|
Melinta Therapeutics
NEW HAVEN, CT and SAN DIEGO, Oct. 9, 2015 (GLOBE NEWSWIRE) -- Melinta Therapeutics, a privately held company developing novel antibiotics to treat serious bacterial infections, today announced...
Melinta Therapeutics Demonstrates Potency of Delafloxacin against Bacteria Associated with Respiratory Tract Infections
September 19, 2015 14:00 ET
|
Melinta Therapeutics
NEW HAVEN, Conn , Sept. 19, 2015 (GLOBE NEWSWIRE) -- Melinta Therapeutics, a privately held company developing novel antibiotics to treat bacterial infections, today announced in vitro results...
Melinta Therapeutics Announces $67M Series 4 Financing
June 10, 2015 07:00 ET
|
Melinta Therapeutics
NEW HAVEN, CT, June 10, 2015 (GLOBE NEWSWIRE) -- NEW HAVEN, CT – June 10, 2015 – Melinta Therapeutics, a privately held Phase 3 company developing novel antibiotics to treat bacterial...
Melinta Therapeutics Joins White House Forum on Antibiotic Stewardship in Commitment to Take Steps to Avert Potential Crisis
June 02, 2015 07:30 ET
|
Melinta Therapeutics
New Haven, CT, June 2, 2015 (GLOBE NEWSWIRE) -- Melinta Therapeutics announced today it is joining with more
than 150 other major food companies, retailers, and human and
animal health stakeholders at...
Melinta Therapeutics Study Demonstrates Significant Burden of Obesity on Patients' Recovery from Acute Bacterial Skin Infections
May 19, 2015 16:00 ET
|
Melinta Therapeutics
New Haven, CT, May 19, 2015 (GLOBE NEWSWIRE) -- Melinta Therapeutics today presented data that show the negative
impact of obesity on patients' recovery from acute bacterial skin
and skin structure...
Melinta Therapeutics Shows that Health-Related Quality-of-Life is higher in ABSSSI Patients Deemed Cured vs Improved after End of Treatment
April 09, 2015 12:02 ET
|
Melinta Therapeutics
New Haven, CT, April 9, 2015 (GLOBE NEWSWIRE) -- Melinta Therapeutics today presented an evaluation of
Health-Related Quality-of-Life (HRQL) in acute bacterial skin and
skin structure infection...
Melinta Therapeutics Secures up to $30 Million from Hercules Technology Growth Capital
February 09, 2015 08:00 ET
|
Melinta Therapeutics
New Haven, Conn, Feb. 9, 2015 (GLOBE NEWSWIRE) -- Melinta Therapeutics announced today that it has entered into a
$30 million growth capital debt financing agreement with Hercules
Technology Growth...
Melinta Therapeutics and Eurofarma Laboratorios Enter into Commercialization and Distribution Agreements for Delafloxacin in Brazil
January 08, 2015 15:08 ET
|
Melinta Therapeutics
NEW HAVEN, Conn. and Sao Paolo, Brazil, Jan. 8, 2015 (GLOBE NEWSWIRE) -- Melinta Therapeutics and Eurofarma Laboratórios, one of the
largest pharmaceutical companies in Brazil, announced that...
Melinta Therapeutics' Lead Candidate Delafloxacin Yields Positive Top-Line Results in Phase 3 Study in Patients with ABSSSI
January 07, 2015 13:40 ET
|
Melinta Therapeutics
New Haven, Conn, Jan. 7, 2015 (GLOBE NEWSWIRE) -- Melinta Therapeutics today
announced positive top-line results from the first of two
Phase 3 PROCEED studies (study RX-3341-302, NCT01811732) to...